option chains Fidelity
Home > Boards > US OTC > Biotechs >

Nuvilex, Inc. (NVLX)

NVLX RSS Feed
Add NVLX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Alydyr, anarmyofme, thnikkamax, lastcall59, TheBestInvest
Search This Board:
Last Post: 4/23/2014 11:07:22 PM - Followers: 446 - Board type: Free - Posts Today: 0

                                      WORK IN PROGRESS                                          


Nuvilex      

NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)

                                            

Nuvilex Company Address
   Nuvilex, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851
   email: info@nuvilex.com


Shares Outstanding:
593,411,348 a/o Dec 13, 2013

Authorized Shares:
N/A

Float:
N/A
For more updated information please visit: 
http://www.otcmarkets.com/stock/NVLX/company-info



Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations
Marlin Molinaro
Marmel Communications, LLC
Phone: (702) 434-8692
email: mmolinarofc@aol.com


                                               

All News Releases: 
http://www.nuvilex.com/latest-news


Nuvilex is a biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box(TM). This unique technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. The Company's treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon chemical constituents of marijuana known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box(TM) technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop "green" approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide.

Nuvilex has acquired worldwide exclusive rights to the cellulose-based live cell-encapsulation technology, also known as Cell-in-a-Box™, and described above, from SG Austria Pte. Ltd. for the development of treatments for any and all types of cancer. The rights to use the cancer drug-activating cells that will be part of Nuvilex’s treatment for advanced pancreatic cancer (see Pancreatic Cancer section of this website) were also acquired. The acquisition of rights to use the Cell-in-a-Box™ technology for the development of treatments for insulin-dependent diabetes has recently been completed.

Austria Nova Demonstration Video


The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool.

 

Medical Marijuana Sciences

 
                                                                                                                                   

                                                       



 


Management Team:
 

Kenneth L. Waggoner, Chief Executive Officer and President:

Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.

Dr. Robert F. Ryan, Chief Scientific Officer:

 

Dr. Robert F. Ryan was named Chief Scientific Officer. Dr. Ryan has broad scientific experience in biochemistry, cell and molecular biology, human genetics, novel therapies, and basic and clinical cancer research, having received his Masters in Biochemistry, Cell and Molecular Biology at The Medical College of Georgia, studying sickle cell anemia. He received his Ph.D. in Molecular Genetics at Thomas Jefferson University characterizing DNA and RNA binding properties of zinc finger proteins. Through his extensive training, his experiences extend across the fields of aging, hemoglobinopathies, gene expression, human diseases, DNA, RNA, proteins and their interactions, stem cell research and applications, oncology, clinical protocols and therapies.

Professionally, Dr. Ryan has become a pioneer in the field of emerging biotechnology, specializing in assisting small companies with insight and bringing products to market through the rigorous FDA approval process. Since 2002, Dr. Ryan served as the Chief Executive Officer of RFR Consulting where he focused on helping businesses in the biotech industry through providing information, grant writing, business management, scientific guidance, FDA regulatory advice, advising investors, and investment acquisition opportunities. With 25 years experience including excellent training at the Wistar Institute, NIH, and NCI, he has participated in basic and clinical investigations and has published and edited research articles in several peer-reviewed journals.

Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:

 

Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Patricia Gruden – Chief Financial Officer and Chairman of the Board:

 

Patricia Gruden is the Chief Financial Officer of the Company and Chairman of the Board.  Ms. Gruden has made a substantial impact on the Company since its inception.  In 1995, Ms. Gruden became cofounder of the company that later became Nuvilex, Inc.  The original company was initiated to develop a software program through accurately tracking produce from the field to the table, including the challenges of shipping, temperature variation and maintenance and everything else concerning the distribution of produce worldwide.  In addition, the Company developed an ozone cleaning system to kill bacteria on produce without leaving harmful residue on the product and without harming the environment. 

Over the years Ms. Gruden has carried out almost every job in the Company, including developer, shipper, President, CEO, Chairman of the Board, CFO and many others.  As a result, she has been intricately aware of all aspects of the Company and its products.  After a brief semi-retirement in 2009-10, Ms. Gruden returned to make arrangements for necessary funding and to assist the Company in changing from a nutraceutical company to a biotechnology company.  Her training has not only included real world experiences of running more than one company, Ms. Gruden embraces every business opportunity with excitement, clarity and focus.  Ms. Gruden has a long history of owning her own businesses and doing so successfully. Additionally, a strong community presence allowed her to act as President of the local Chamber of Commerce and Arizona Small Business Association.  She has also been active in Habitat for Humanity, shelters for abused women and children and the Ronald McDonald House.

 

Stock Chart http://www.otcmarkets.com/stock/NVLX/chart
Company Info http://www.otcmarkets.com/stock/NVLX/company-info
Recent News http://www.otcmarkets.com/stock/NVLX/news
Financials http://www.otcmarkets.com/stock/NVLX/financials
Filings and Disclosure http://www.otcmarkets.com/stock/NVLX/filings
Short Sales http://www.otcmarkets.com/stock/NVLX/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/NVLX/insider-transactions
Research Reports http://www.otcmarkets.com/stock/NVLX/research
Summary http://finance.yahoo.com/q?s=NVLX
Historical Prices http://finance.yahoo.com/q/hp?s=NVLX+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=NVLX
Basic Chart http://finance.yahoo.com/q/bc?s=NVLX+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=NVLX+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=NVLX+Headlines
Press Releases http://finance.yahoo.com/q/p?s=NVLX+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=NVLX+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=NVLX+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=NVLX+Industry
Major Holders http://finance.yahoo.com/q/mh?s=NVLX+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=NVLX+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=NVLX+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=NVLX
Balance Sheet http://finance.yahoo.com/q/bs?s=NVLX
Cash Flow http://finance.yahoo.com/q/cf?s=NVLX+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/NVLX
Market Watch http://www.marketwatch.com/investing/stock/NVLX
Bloomberg http://www.bloomberg.com/quote/NVLX:US
Morningstar http://quotes.morningstar.com/stock/s?t=NVLX
Bussinessweek http://investing.businessweek.com/research/st...icker=NVLX
Barchart http://www.barchart.com/quotes/stocks/NVLX
OTC Short Report http://otcshortreport.com/index.php?index=NVLX
Investopedia http://www.investopedia.com/markets/stocks/NVLX/?wa=0


                                 

PostSubject
#20096  Sticky Note Im sure this has been read by many, rollinlow 04/23/14 10:46:08 AM
#20023  Sticky Note NUVILEX UPDATED TODAY for SHORTING on TheBestInvest 04/22/14 01:44:40 PM
#19932  Sticky Note NVLX UPDATED TODAY for NEW TOUTING on the Alydyr 04/21/14 09:36:23 AM
#18112  Sticky Note EVERYONE please keep your posts on-topic. The topic IH Geek [Dave] 03/14/14 12:28:20 PM
#20166   I understand that most of the PR's are Let-it-rise 04/23/14 10:22:08 PM
#20165   I've never been able to short sell an Alydyr 04/23/14 10:11:15 PM
#20164   OTSY, thanks for the great information. I Let-it-rise 04/23/14 10:10:49 PM
#20163   I thought in 2008 the SEC made it Let-it-rise 04/23/14 10:05:00 PM
#20161   That is a great article. Some here will Otsy 04/23/14 09:49:37 PM
#20160   How many patients are currently enrolled in the alsoconcerned 04/23/14 09:03:21 PM
#20158   Added https://www.youtube.com/watch?v=3JuvVKZHk7E&noredirect=1 to the iBox. I th TheBestInvest 04/23/14 07:59:46 PM
#20156   I still have this message kept. Great article TheBestInvest 04/23/14 07:13:56 PM
#20155   you on right on the money with your vinnybotz 04/23/14 06:54:59 PM
#20153   Emmmci, your point is to be well noted. Peacefulwendy 04/23/14 06:38:07 PM
#20152   vinny, I have been a fan since I Peacefulwendy 04/23/14 06:29:27 PM
#20151   Today was not a bad day. What I Otsy 04/23/14 06:05:58 PM
#20150   welcome! .35 is and will be a steal!!! vinnybotz 04/23/14 05:47:16 PM
#20148   Amen. Exactly what I was trying to say ducks2312 04/23/14 03:59:26 PM
#20147   Let the chips fall where they may, I'm Stks_Not_Toys 04/23/14 03:51:04 PM
#20146   specular -- you put the name cytochrome p450 Stks_Not_Toys 04/23/14 03:48:16 PM
#20145   I have read about cytochrome P450....and they are bulldurham 04/23/14 03:13:54 PM
#20144   We some more news to get this rally Pennystockplayer 04/23/14 03:13:44 PM
#20143   if this is your example of DD (Wikipedia) specular 04/23/14 03:11:48 PM
#20142   You may want to go down to the Emmmci 04/23/14 03:11:11 PM
#20141   Yes. Because according to just about every drug thnikkamax 04/23/14 03:08:56 PM
#20140   Cytochrome P450 Stks_Not_Toys 04/23/14 03:05:08 PM
#20139   go on the austrianova web site and click specular 04/23/14 02:59:22 PM
#20138   You do understand what Cell_in_a_Box is don't you... bulldurham 04/23/14 02:48:10 PM
#20135   This is a free market, right? I Alydyr 04/23/14 02:25:56 PM
#20134   Yessir. I understand. ducks2312 04/23/14 02:18:52 PM
#20133   were aiming for it is the point I believe.. tek1 04/23/14 02:15:12 PM
#20131   Would it be illegal for a company to Peacefulwendy 04/23/14 02:09:08 PM
#20130   Thanks for clearing all that up! Peacefulwendy 04/23/14 02:05:16 PM
#20129   Short interest reports are typically updated and published Alydyr 04/23/14 02:05:02 PM
#20127   You guys are talking long term yet most ducks2312 04/23/14 01:52:23 PM
#20126   Isn't the short sale report for sales issued Peacefulwendy 04/23/14 01:51:10 PM
#20125   What are those reasons? Ifosfamide is 1/3 ducks2312 04/23/14 01:47:14 PM
#20124   Very nice post, rollinlow! It would be Peacefulwendy 04/23/14 01:44:50 PM
#20123   yes there is concern for long term because tek1 04/23/14 01:43:18 PM
#20122   I agree - it is a good trade. specular 04/23/14 01:38:16 PM
#20121   absolutely I agree. but doing DD on pinks tek1 04/23/14 01:28:43 PM
#20120   Then it would be a great question to specular 04/23/14 01:21:44 PM
#20119   From what I saw a couple months ago moneyhungary 04/23/14 01:13:28 PM
#20117   What I see is a little dip from TheBestInvest 04/23/14 01:01:09 PM
#20115   What I see here is no one wants bulldurham 04/23/14 12:51:47 PM
#20114   Looks like NVLX promoter's and insiders are dumping Alydyr 04/23/14 12:48:37 PM
#20112   Just in case some of you haven't seen Emmmci 04/23/14 12:28:16 PM
#20111   this little bio is just getting started...and they bulldurham 04/23/14 12:27:55 PM
#20110   Let's just lay this to rest about dilution bulldurham 04/23/14 12:25:37 PM
#20106   35 MILLION common shares of NVLX were issued Alydyr 04/23/14 11:43:46 AM
#20105   well the leading cancer doctor in the world tek1 04/23/14 11:13:26 AM
#20103   Nuvilex is part owner of Austrianova because they bulldurham 04/23/14 11:05:40 AM
#20102   I hate to sound facetious but...No kidding, really Otsy 04/23/14 11:02:01 AM
#20101   Again, incorrect. Many companies (possibly NVLX) will Alydyr 04/23/14 11:00:41 AM
PostSubject